{"id":8106,"date":"2026-09-14T17:00:33","date_gmt":"2026-09-14T15:00:33","guid":{"rendered":"https:\/\/oncopeptides.com\/?page_id=8106"},"modified":"2026-09-15T09:52:39","modified_gmt":"2026-09-15T07:52:39","slug":"oncopeptides-riktar-unik-forskning-mot-obotlig-cancer","status":"publish","type":"page","link":"https:\/\/oncopeptides.com\/sv\/oncopeptides-riktar-unik-forskning-mot-obotlig-cancer\/","title":{"rendered":"Oncopeptides riktar unik forskning mot obotlig cancer"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"8106\" class=\"elementor elementor-8106\" data-elementor-post-type=\"page\">\n\t\t\t\t<style>\n                .elementor-element-1e41e6e{\n                --padding-top: var(--webien-padding-top-default);\n                --padding-right: var(--webien-padding-right-default);\n                --padding-bottom: var(--webien-padding-bottom-default);\n                --padding-left: var(--webien-padding-left-default);\n                }\n            <\/style><div class=\"webien-container-padding-default elementor-element elementor-element-1e41e6e elementor-hidden-mobile dotted-top e-flex e-con-boxed elementor-invisible e-con e-parent\" data-id=\"1e41e6e\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;fadeIn&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-6b2d322 elementor-widget elementor-widget-spacer\" data-id=\"6b2d322\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-00436c3 elementor-widget elementor-widget-webien_breadcrumbs\" data-id=\"00436c3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"webien_breadcrumbs.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"item\":{\"@id\":\"https:\/\/oncopeptides.com\/sv\/\",\"name\":\"Hem\"}},{\"@type\":\"ListItem\",\"position\":2,\"item\":{\"@id\":\"https:\/\/oncopeptides.com\/sv\/oncopeptides-riktar-unik-forskning-mot-obotlig-cancer\/\",\"name\":\"Oncopeptides riktar unik forskning mot obotlig cancer\"}}]}<\/script>    <div class=\"breadcrumb-wrapper\">\n        <ul class=\"breadcrumbs\" id=\"breadcrumbs\">\n                                                                        <li class=\"item \">\n                                            <a href=\"https:\/\/oncopeptides.com\/sv\/\">Hem<\/a>\n                                            <\/li>\n                                                                                        <li class=\"separator\">\n                            \/                        <\/li>\n                                            <li class=\"item current\">\n                                            <a href=\"https:\/\/oncopeptides.com\/sv\/oncopeptides-riktar-unik-forskning-mot-obotlig-cancer\/\">Oncopeptides riktar unik forskning mot obotlig cancer<\/a>\n                                            <\/li>\n                                    <\/ul>\n\n            <\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-6eab5f0{\n                --padding-top: var(--webien-padding-top-l);\n                --padding-right: var(--webien-padding-right-l);\n                --padding-bottom: var(--webien-padding-bottom-l);\n                --padding-left: var(--webien-padding-left-l);\n                }\n            <\/style><div class=\"webien-container-padding-l elementor-element elementor-element-6eab5f0 e-flex e-con-boxed e-con e-parent\" data-id=\"6eab5f0\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<style>\n                .elementor-element-2936620{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-2936620 e-con-full main e-flex e-con e-child\" data-id=\"2936620\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-01eb9bc elementor-widget elementor-widget-heading\" data-id=\"01eb9bc\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">Oncopeptides riktar unik forskning mot obotlig cancer<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f8242b2 elementor-widget elementor-widget-image\" data-id=\"f8242b2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<webien-image class=\" has-thumb ratio-original\">\r\n\t<img fetchpriority=\"high\" decoding=\"async\" src=\"https:\/\/c1.webien.cloud\/pixel.webp\" width=\"2560\" height=\"1709\" data-srcset=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/03\/istock-1327624070-scaled.jpg\" data-original=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/03\/istock-1327624070-scaled.jpg\" data-optimize=\"1\" data-useoriginal=\"0\" data-ratio=\"none\" data-sizes=\"auto\" data-focus=\"attention\" class=\"main lazyload\" title=\"Shot of two young scientists conducting medical research in a laboratory\" alt=\"\" \/>\r\n\t\r\n\t<img decoding=\"async\" width=\"2560\" height=\"1709\" src=\"https:\/\/wrooom.webien.io\/eyJpbWFnZVVybCI6Imh0dHBzOi8vb25jb3BlcHRpZGVzLmNvbS93cC1jb250ZW50L3VwbG9hZHMvMjAyNi8wMy9pc3RvY2stMTMyNzYyNDA3MC1zY2FsZWQuanBnIiwicHVibGljS2V5Ijoibm9LZXkiLCJlZGl0cyI6eyJyZXNpemUiOnsid2lkdGgiOjE1MCwiaGVpZ2h0IjoxNTAsImZpdCI6Imluc2lkZSIsInBvc2l0aW9uIjoiYXR0ZW50aW9uIiwid2l0aG91dEVubGFyZ2VtZW50Ijp0cnVlfSwiYmx1ciI6MTJ9fQ==\" class=\"thumb\" \/>\r\n\t<\/webien-image>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-db43ecf haus-accordion elementor-hidden-desktop elementor-hidden-tablet elementor-widget elementor-widget-n-accordion\" data-id=\"db43ecf\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;default_state&quot;:&quot;all_collapsed&quot;,&quot;n_accordion_animation_duration&quot;:{&quot;unit&quot;:&quot;ms&quot;,&quot;size&quot;:200,&quot;sizes&quot;:[]},&quot;max_items_expended&quot;:&quot;one&quot;}\" data-widget_type=\"nested-accordion.default\">\n\t\t\t\t\t\t\t<div class=\"e-n-accordion\" aria-label=\"Accordion. Open links with Enter or Space, close with Escape, and navigate with Arrow Keys\">\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-2290\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"1\" tabindex=\"0\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-2290\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> On this page <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><i aria-hidden=\"true\" class=\"onco onco-Minus\"><\/i><\/span>\n\t\t\t<span class='e-closed'><i aria-hidden=\"true\" class=\"onco onco-Plus\"><\/i><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<style>\n                .elementor-element-aace8ea{\n                --padding-top: var(--webien-padding-top-default);\n                --padding-right: var(--webien-padding-right-default);\n                --padding-bottom: var(--webien-padding-bottom-default);\n                --padding-left: var(--webien-padding-left-default);\n                }\n            <\/style><div class=\"webien-container-padding-default elementor-element elementor-element-aace8ea e-con-full e-flex e-con e-child\" role=\"region\" aria-labelledby=\"e-n-accordion-item-2290\" data-id=\"aace8ea\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-4b1bc97 elementor-widget elementor-widget-webien-toc\" data-id=\"4b1bc97\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"webien-toc.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<style>.chapter-heading .anchor { background-image: url(https:\/\/oncopeptides.com\/wp-content\/plugins\/webien-plugin\/src\/Elementor\/Widgets\/TOC\/images\/link.svg); }<\/style><style>@media (min-width: 0px) {\n                #webien-toc-widget-8bc8114f43 .narrow-view-btns,\n                #webien-toc-widget-8bc8114f43 .narrow-view {\n                    display: none;\n                }\n                #webien-toc-widget-8bc8114f43 .standard-view {\n                    display: block;\n                }\n            }<\/style><div class=\"webien-toc-widget-toc\" id=\"webien-toc-widget-8bc8114f43\" data-unique=\"8bc8114f43\">\n\n    <div class=\"inner\" :class=\"{ready:appReady}\">\n\n        <div class=\"standard-view\">\n            <div class=\"chapters\" v-show=\"chapters.length\">\n                <button @click=\"scrollToChapter(chapter)\" v-for=\"chapter in chapters\" :class=\"[{active:chapter.active}, 'level-' + chapter.level]\">{{chapter.title}}<\/button>\n            <\/div>\n        <\/div>\n\n\n        <div class=\"narrow-view-btns\">\n            <button class=\"open\" @click=\"openNarrowView()\">\n                <?xml version=\"1.0\" encoding=\"UTF-8\"?>\n<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" width=\"50pt\" height=\"50pt\" viewBox=\"0 0 50 50\" version=\"1.1\">\n<g id=\"surface2290\">\n<path style=\" stroke:none;fill-rule:nonzero;fill:rgb(0%,0%,0%);fill-opacity:1;\" d=\"M 6.769531 12.5 C 5.332031 12.5 4.167969 13.664062 4.167969 15.105469 C 4.167969 16.542969 5.332031 17.707031 6.769531 17.707031 C 8.210938 17.707031 9.375 16.542969 9.375 15.105469 C 9.375 13.664062 8.210938 12.5 6.769531 12.5 Z M 14.0625 13.542969 C 13.5 13.535156 12.976562 13.828125 12.691406 14.316406 C 12.40625 14.804688 12.40625 15.40625 12.691406 15.890625 C 12.976562 16.378906 13.5 16.675781 14.0625 16.667969 L 44.269531 16.667969 C 44.835938 16.675781 45.359375 16.378906 45.640625 15.890625 C 45.925781 15.40625 45.925781 14.804688 45.640625 14.316406 C 45.359375 13.828125 44.835938 13.535156 44.269531 13.542969 Z M 6.769531 22.917969 C 5.332031 22.917969 4.167969 24.082031 4.167969 25.519531 C 4.167969 26.960938 5.332031 28.125 6.769531 28.125 C 8.210938 28.125 9.375 26.960938 9.375 25.519531 C 9.375 24.082031 8.210938 22.917969 6.769531 22.917969 Z M 14.0625 23.957031 C 13.5 23.949219 12.976562 24.246094 12.691406 24.734375 C 12.40625 25.21875 12.40625 25.820312 12.691406 26.308594 C 12.976562 26.796875 13.5 27.089844 14.0625 27.082031 L 44.269531 27.082031 C 44.835938 27.089844 45.359375 26.796875 45.640625 26.308594 C 45.925781 25.820312 45.925781 25.21875 45.640625 24.734375 C 45.359375 24.246094 44.835938 23.949219 44.269531 23.957031 Z M 6.769531 33.332031 C 5.332031 33.332031 4.167969 34.5 4.167969 35.9375 C 4.167969 37.375 5.332031 38.542969 6.769531 38.542969 C 8.210938 38.542969 9.375 37.375 9.375 35.9375 C 9.375 34.5 8.210938 33.332031 6.769531 33.332031 Z M 14.0625 34.375 C 13.5 34.367188 12.976562 34.664062 12.691406 35.148438 C 12.40625 35.636719 12.40625 36.238281 12.691406 36.726562 C 12.976562 37.210938 13.5 37.507812 14.0625 37.5 L 44.269531 37.5 C 44.835938 37.507812 45.359375 37.210938 45.640625 36.726562 C 45.925781 36.238281 45.925781 35.636719 45.640625 35.148438 C 45.359375 34.664062 44.835938 34.367188 44.269531 34.375 Z M 14.0625 34.375 \"\/>\n<\/g>\n<\/svg>\n                            <\/button>\n\n            <button class=\"scroll-up\" @click=\"scrollToTop()\">\n                <?xml version=\"1.0\" encoding=\"UTF-8\"?>\n<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" width=\"50pt\" height=\"50pt\" viewBox=\"0 0 50 50\" version=\"1.1\">\n<g id=\"surface3521\">\n<path style=\" stroke:none;fill-rule:nonzero;fill:rgb(0%,0%,0%);fill-opacity:1;\" d=\"M 24.457031 6.25 C 24.050781 6.257812 23.660156 6.421875 23.375 6.707031 L 8.792969 21.292969 C 8.382812 21.683594 8.21875 22.265625 8.359375 22.8125 C 8.503906 23.359375 8.929688 23.789062 9.480469 23.929688 C 10.027344 24.074219 10.609375 23.910156 11 23.5 L 22.917969 11.585938 L 22.917969 42.1875 C 22.910156 42.75 23.203125 43.273438 23.691406 43.558594 C 24.179688 43.84375 24.78125 43.84375 25.265625 43.558594 C 25.753906 43.273438 26.050781 42.75 26.042969 42.1875 L 26.042969 11.585938 L 37.957031 23.5 C 38.351562 23.910156 38.929688 24.074219 39.480469 23.929688 C 40.027344 23.789062 40.453125 23.359375 40.597656 22.8125 C 40.738281 22.265625 40.574219 21.683594 40.167969 21.292969 L 25.582031 6.707031 C 25.285156 6.410156 24.878906 6.242188 24.457031 6.25 Z M 24.457031 6.25 \"\/>\n<\/g>\n<\/svg>\n            <\/button>\n        <\/div>\n\n\n\n\n        <div class=\"narrow-view\" :class=\"{active:narrow.open}\">\n            <div class=\"bkg\" @click=\"closeNarrowView()\"><\/div>\n            <div class=\"inner\" :class=\"{ready:appReady}\">\n                <div class=\"top\"><\/div>\n                <div class=\"chapters\" v-show=\"chapters.length\">\n                    <button @click=\"scrollToChapter(chapter)\" v-for=\"chapter in chapters\" :class=\"[{active:chapter.active}, 'level-' + chapter.level]\">{{chapter.title}}<\/button>\n                <\/div>\n                <div class=\"bottom\"><\/div>\n            <\/div>\n        <\/div>\n\n\n\n\n    <\/div>\n\n\n<\/div>\n\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c95940a dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"c95940a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-bb3c1cf elementor-widget elementor-widget-text-editor\" data-id=\"bb3c1cf\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p><em>Oncopeptides \u00e4r ett litet svenskt biotechbolag med en stor ambition: att rikta sin unika forskning mot cancerformer d\u00e4r behovet av nya behandlingar \u00e4r som st\u00f6rst. Med ett l\u00e4kemedel mot multipelt myelom &#8211; en obotlig blodcancer som uppst\u00e5r i benm\u00e4rgen &#8211; som grund, och en ny forskningssatsning mot hj\u00e4rncancer, vill bolaget visa att vetenskap och samarbete kan v\u00e4ga tyngre \u00e4n storlek i kampen mot sjukdomar som fortfarande inte g\u00e5r att bota.<\/em><\/p><h2>Forskning som f\u00f6rl\u00e4nger livet f\u00f6r de sv\u00e5rast drabbade<\/h2><p>Oncopeptides grundades \u00e5r 2000 kring en uppt\u00e4ckt vid Uppsala universitet och har sedan dess byggt en egen teknologiplattform, PDC (peptid-l\u00e4kemedelskonjugat), d\u00e4r en cellskadande, alkylerande substans kopplas till en peptid. Peptiden g\u00f6r att l\u00e4kemedlet snabbt och selektivt tas upp av cancerceller, d\u00e4r det bryts ner och fris\u00e4tter sin alkylerande best\u00e5ndsdel inne i tum\u00f6ren &#8211; en mekanism som ger god effekt utan att \u00f6ka biverkningarna j\u00e4mf\u00f6rt med \u00e4ldre alkylerare.<\/p><p>Bolaget driver \u00e4ven SPiKE, en andra teknologiplattform som aktiverar kroppens eget immunf\u00f6rsvar mot cancer. Genom att bygga vidare p\u00e5 modern immunterapi fokuserar SPiKE s\u00e4rskilt p\u00e5 att styra kroppens \u201dnaturliga m\u00f6rdarceller\u201d (NK-celler) direkt mot tum\u00f6ren.<\/p><p>Plattformens f\u00f6rsta PDC-produkt godk\u00e4ndes av EU:s l\u00e4kemedelsmyndighet EMA under 2022 f\u00f6r behandling av multipelt myelom, en obotlig cancerform i benm\u00e4rgen. L\u00e4kemedlet \u00e4r just nu godk\u00e4nt f\u00f6r patienter som f\u00e5tt minst tre tidigare behandlingslinjer och vars sjukdom \u00e4r resistent mot flera olika l\u00e4kemedelsklasser &#8211; det vill s\u00e4ga som fj\u00e4rdelinjebehandling f\u00f6r de sv\u00e5rast sjuka patienterna i sent skede av sjukdomen.<\/p><p>Synen p\u00e5 vetenskap och samarbete genomsyrar hela Oncopeptides verksamhet &#8211; men ocks\u00e5 en tydlig \u00f6vertygelse om vad forskningen faktiskt ska ge patienterna: mer tid.<\/p><p>&#8221;Man kan faktiskt f\u00f6rl\u00e4nga livet ganska mycket&#8221;, som vd Sofia Heigis har beskrivit det i en intervju om hur bolagets l\u00e4kemedel anv\u00e4nds mellan olika immunterapier. Det \u00e4r den logiken &#8211; att varje ny behandlingsm\u00f6jlighet \u00e4r en chans till l\u00e4ngre liv f\u00f6r de sv\u00e5rast sjuka &#8211; som bolaget menar ligger till grund f\u00f6r b\u00e5de utvecklingen av PDC-plattformen och arbetet med patienterna.<\/p><p><a href=\"https:\/\/oncopeptides.com\/sv\/oncopeptalks\/kommentar-till-rapporten-for-andra-kvartalet-2026\/\" target=\"_blank\" rel=\"noopener\">Lyssna p\u00e5 diskussionen med Sofia Heigis i det senaste avsnittet av Oncopeptides podcast h\u00e4r<\/a><\/p><h2>Framg\u00e5ngarna inom multipelt myelom<\/h2><p>Oncopeptides l\u00e4kemedel anv\u00e4nds idag av kliniker i Tyskland, \u00d6sterrike, Italien, Spanien och Grekland. Bolaget bed\u00f6mer den europeiska marknadspotentialen till omkring 1,5 miljarder kronor om \u00e5ret, baserat p\u00e5 dagens godk\u00e4nda indikation som fj\u00e4rdelinjebehandling. Under det andra kvartalet 2026 v\u00e4xte bolagets nettooms\u00e4ttning med 62 procent j\u00e4mf\u00f6rt med motsvarande period f\u00f6reg\u00e5ende \u00e5r.<\/p><p>F\u00f6rklaringen till att marknaden forts\u00e4tter v\u00e4xa, trots konkurrens fr\u00e5n nyare behandlingar, \u00e4r enligt bolaget att n\u00e4stan alla patienter med multipelt myelom f\u00f6rr eller senare \u00e5terfaller och beh\u00f6ver ytterligare behandlingslinjer. Jakob Lindberg, en av bolagets grundare och idag vetenskaplig r\u00e5dgivare, beskriver det som en kamp om marknadsandelar mellan behandling och sjukdom, d\u00e4r Oncopeptides l\u00e4kemedel idag \u201ctar marknadsandelar fr\u00e5n d\u00f6den\u201d.<\/p><p><a href=\"https:\/\/oncopeptides.com\/sv\/oncopeptalks\/oncopeptides-da-och-nu\/\" target=\"_blank\" rel=\"noopener\">Lyssna p\u00e5 intervjun med Jakob Lindberg i Oncopeptides podcast h\u00e4r<\/a><\/p><p>I juni 2026 presenterade bolaget dessutom s\u00e5 kallad real world-data fr\u00e5n \u00f6ver 800 behandlade patienter i Europa vid hematologikongressen EHA i Stockholm &#8211; det hittills st\u00f6rsta dataunderlaget f\u00f6r hur l\u00e4kemedlet fungerar utanf\u00f6r kliniska studier. Bland resultaten fanns den st\u00f6rsta rapporten hittills om hur bolagets l\u00e4kemedel anv\u00e4nds i en verklig klinisk vardag, vilken visade att l\u00e4kemedlet var b\u00e5de s\u00e4kert och effektivt \u00e4ven hos tungt f\u00f6rbehandlade patienter &#8211; inklusive de som tidigare f\u00e5tt immunterapi.<\/p><p>Enligt vd Sofia Heigis \u00e4r det inte bara bolagets egen bed\u00f6mning, utan bygger p\u00e5 direkt feedback och verkliga erfarenheter fr\u00e5n de l\u00e4kare som faktiskt anv\u00e4nder l\u00e4kemedlet i sin kliniska vardag. Det \u00e4r den kombinationen &#8211; egna data och kundernas r\u00f6ster &#8211; som hon menar bekr\u00e4ftar att det medicinska behovet fortfarande finns kvar, trots ett behandlingslandskap i snabb f\u00f6r\u00e4ndring.<\/p><h2>V\u00e4gen fram\u00e5t: ny behandlingslinje och ny indikation<\/h2><p><img decoding=\"async\" class=\"size-full wp-image-4875\" src=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/02\/istock-1127105013-scaled.jpg\" alt=\"\" width=\"2560\" height=\"1634\" srcset=\"https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/02\/istock-1127105013-scaled.jpg 2560w, https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/02\/istock-1127105013-300x191.jpg 300w, https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/02\/istock-1127105013-1024x654.jpg 1024w, https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/02\/istock-1127105013-768x490.jpg 768w, https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/02\/istock-1127105013-1536x980.jpg 1536w, https:\/\/oncopeptides.com\/wp-content\/uploads\/2026\/02\/istock-1127105013-2048x1307.jpg 2048w\" sizes=\"(max-width: 2560px) 100vw, 2560px\" \/><\/p><p>Bolagets n\u00e4rmaste tillv\u00e4xtplan handlar om att bredda den godk\u00e4nda anv\u00e4ndningen av bolagets l\u00e4kemedel. Oncopeptides har l\u00e4mnat in en typ II-variationsans\u00f6kan till EMA f\u00f6r att utvidga l\u00e4kemedlets anv\u00e4ndning fr\u00e5n fj\u00e4rde till tredje behandlingslinjen, vilket enligt bolaget skulle kunna f\u00f6rdubbla den adresserbara patientpopulationen i Europa. Besked v\u00e4ntas mellan september och november 2026.<\/p><p>Parallellt riktar Oncopeptides sin teknologi mot ett helt nytt sjukdomsomr\u00e5de: glioblastom, en aggressiv hj\u00e4rntum\u00f6r d\u00e4r behandlingslandskapet knappt f\u00f6r\u00e4ndrats p\u00e5 tjugo \u00e5r, mest p\u00e5 grund av blod-hj\u00e4rnbarri\u00e4ren som hindrar de flesta l\u00e4kemedel fr\u00e5n att n\u00e5 fram till tum\u00f6ren. Under sommaren 2026 doserades den f\u00f6rsta patienten i en klinisk studie i Oslo. Den globala marknaden bed\u00f6ms av bolaget till omkring 8 miljarder dollar, motsvarande ungef\u00e4r 80 miljarder kronor.<\/p><p>\u201cV\u00e5r vetenskapliga motivering \u00e4r stark. Den \u00e4r intressant och logisk\u201d, s\u00e4ger Sofia Heigis och syftar p\u00e5 att bolagets verkningsmekanism angriper tum\u00f6rceller p\u00e5 tv\u00e5 olika s\u00e4tt samtidigt &#8211; genom att skada b\u00e5de DNA:t i cellk\u00e4rnan och cellernas &#8221;kraftverk&#8221;, mitokondrierna &#8211; n\u00e5got som kan vara extra v\u00e4rdefullt vid glioblastom, d\u00e4r en enskild mitokondrie kan f\u00f6rs\u00f6rja flera tum\u00f6rceller med energi. I djurmodeller har bolaget dessutom sett att substansen tar sig \u00f6ver blod-hj\u00e4rnbarri\u00e4ren med h\u00f6g biotillg\u00e4nglighet, vilket \u00e4r den bakomliggande utmaning som gjort att s\u00e5 m\u00e5nga tidigare l\u00e4kemedelsf\u00f6rs\u00f6k mot glioblastom misslyckats.<\/p><p><a href=\"https:\/\/oncopeptides.com\/sv\/oncopeptalks\/glioblastom-nasta-kapitel-for-oncopeptides\/\" target=\"_blank\" rel=\"noopener\">Lyssna p\u00e5 diskussionen om glioblastom i Oncopeptides podcast h\u00e4r<\/a><\/p><h2>Med vetenskapen som ledsagare<\/h2><p>Vare sig det handlar om att n\u00e5 fler patienter med multipelt myelom eller om att ta sig an en helt ny sjukdom som glioblastom, \u00e4r utg\u00e5ngspunkten densamma: att l\u00e5ta vetenskapen peka ut v\u00e4gen dit behovet \u00e4r som st\u00f6rst, och att g\u00f6ra det tillsammans med andra &#8211; forskare, kliniker och f\u00f6rskrivande l\u00e4kare &#8211; snarare \u00e4n att s\u00f6ka sig dit konkurrensen \u00e4r som minst. Det \u00e4r den inst\u00e4llningen &#8211; envis, principfast och byggd p\u00e5 samarbete mellan gammal kunskap och ny &#8211; som Oncopeptides menar har tagit bolaget fr\u00e5n ett litet rum p\u00e5 Karolinska institutet till ett godk\u00e4nt cancerl\u00e4kemedel i Europa, och som nu ska avg\u00f6ra om n\u00e4sta kapitel kan skrivas inom hj\u00e4rntum\u00f6rer.<\/p><p><a href=\"http:\/\/oncopeptides.com\/sv\/om-oss\" target=\"_blank\" rel=\"noopener\">Se filmen om Oncopeptides resa och syn p\u00e5 vetenskap h\u00e4r<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-b50edcf{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-b50edcf e-con-full elementor-hidden-mobile e-flex e-con e-child\" data-id=\"b50edcf\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<style>\n                .elementor-element-3565352{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-3565352 e-con-full e-flex e-con e-child\" data-id=\"3565352\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;sticky&quot;:&quot;top&quot;,&quot;sticky_offset&quot;:120,&quot;sticky_parent&quot;:&quot;yes&quot;,&quot;sticky_on&quot;:[&quot;desktop&quot;,&quot;tablet&quot;,&quot;mobile&quot;],&quot;sticky_effects_offset&quot;:0,&quot;sticky_anchor_link_offset&quot;:0}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-f962035 elementor-widget elementor-widget-heading\" data-id=\"f962035\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">P\u00e5 denna sida<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1b4dbf6 elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"1b4dbf6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-acec89d elementor-widget elementor-widget-webien-toc\" data-id=\"acec89d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"webien-toc.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<style>.chapter-heading .anchor { background-image: url(https:\/\/oncopeptides.com\/wp-content\/plugins\/webien-plugin\/src\/Elementor\/Widgets\/TOC\/images\/link.svg); }<\/style><style>@media (min-width: 0px) {\n                #webien-toc-widget-a079ce992c .narrow-view-btns,\n                #webien-toc-widget-a079ce992c .narrow-view {\n                    display: none;\n                }\n                #webien-toc-widget-a079ce992c .standard-view {\n                    display: block;\n                }\n            }<\/style><div class=\"webien-toc-widget-toc\" id=\"webien-toc-widget-a079ce992c\" data-unique=\"a079ce992c\">\n\n    <div class=\"inner\" :class=\"{ready:appReady}\">\n\n        <div class=\"standard-view\">\n            <div class=\"chapters\" v-show=\"chapters.length\">\n                <button @click=\"scrollToChapter(chapter)\" v-for=\"chapter in chapters\" :class=\"[{active:chapter.active}, 'level-' + chapter.level]\">{{chapter.title}}<\/button>\n            <\/div>\n        <\/div>\n\n\n        <div class=\"narrow-view-btns\">\n            <button class=\"open\" @click=\"openNarrowView()\">\n                <?xml version=\"1.0\" encoding=\"UTF-8\"?>\n<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" width=\"50pt\" height=\"50pt\" viewBox=\"0 0 50 50\" version=\"1.1\">\n<g id=\"surface2290\">\n<path style=\" stroke:none;fill-rule:nonzero;fill:rgb(0%,0%,0%);fill-opacity:1;\" d=\"M 6.769531 12.5 C 5.332031 12.5 4.167969 13.664062 4.167969 15.105469 C 4.167969 16.542969 5.332031 17.707031 6.769531 17.707031 C 8.210938 17.707031 9.375 16.542969 9.375 15.105469 C 9.375 13.664062 8.210938 12.5 6.769531 12.5 Z M 14.0625 13.542969 C 13.5 13.535156 12.976562 13.828125 12.691406 14.316406 C 12.40625 14.804688 12.40625 15.40625 12.691406 15.890625 C 12.976562 16.378906 13.5 16.675781 14.0625 16.667969 L 44.269531 16.667969 C 44.835938 16.675781 45.359375 16.378906 45.640625 15.890625 C 45.925781 15.40625 45.925781 14.804688 45.640625 14.316406 C 45.359375 13.828125 44.835938 13.535156 44.269531 13.542969 Z M 6.769531 22.917969 C 5.332031 22.917969 4.167969 24.082031 4.167969 25.519531 C 4.167969 26.960938 5.332031 28.125 6.769531 28.125 C 8.210938 28.125 9.375 26.960938 9.375 25.519531 C 9.375 24.082031 8.210938 22.917969 6.769531 22.917969 Z M 14.0625 23.957031 C 13.5 23.949219 12.976562 24.246094 12.691406 24.734375 C 12.40625 25.21875 12.40625 25.820312 12.691406 26.308594 C 12.976562 26.796875 13.5 27.089844 14.0625 27.082031 L 44.269531 27.082031 C 44.835938 27.089844 45.359375 26.796875 45.640625 26.308594 C 45.925781 25.820312 45.925781 25.21875 45.640625 24.734375 C 45.359375 24.246094 44.835938 23.949219 44.269531 23.957031 Z M 6.769531 33.332031 C 5.332031 33.332031 4.167969 34.5 4.167969 35.9375 C 4.167969 37.375 5.332031 38.542969 6.769531 38.542969 C 8.210938 38.542969 9.375 37.375 9.375 35.9375 C 9.375 34.5 8.210938 33.332031 6.769531 33.332031 Z M 14.0625 34.375 C 13.5 34.367188 12.976562 34.664062 12.691406 35.148438 C 12.40625 35.636719 12.40625 36.238281 12.691406 36.726562 C 12.976562 37.210938 13.5 37.507812 14.0625 37.5 L 44.269531 37.5 C 44.835938 37.507812 45.359375 37.210938 45.640625 36.726562 C 45.925781 36.238281 45.925781 35.636719 45.640625 35.148438 C 45.359375 34.664062 44.835938 34.367188 44.269531 34.375 Z M 14.0625 34.375 \"\/>\n<\/g>\n<\/svg>\n                            <\/button>\n\n            <button class=\"scroll-up\" @click=\"scrollToTop()\">\n                <?xml version=\"1.0\" encoding=\"UTF-8\"?>\n<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" width=\"50pt\" height=\"50pt\" viewBox=\"0 0 50 50\" version=\"1.1\">\n<g id=\"surface3521\">\n<path style=\" stroke:none;fill-rule:nonzero;fill:rgb(0%,0%,0%);fill-opacity:1;\" d=\"M 24.457031 6.25 C 24.050781 6.257812 23.660156 6.421875 23.375 6.707031 L 8.792969 21.292969 C 8.382812 21.683594 8.21875 22.265625 8.359375 22.8125 C 8.503906 23.359375 8.929688 23.789062 9.480469 23.929688 C 10.027344 24.074219 10.609375 23.910156 11 23.5 L 22.917969 11.585938 L 22.917969 42.1875 C 22.910156 42.75 23.203125 43.273438 23.691406 43.558594 C 24.179688 43.84375 24.78125 43.84375 25.265625 43.558594 C 25.753906 43.273438 26.050781 42.75 26.042969 42.1875 L 26.042969 11.585938 L 37.957031 23.5 C 38.351562 23.910156 38.929688 24.074219 39.480469 23.929688 C 40.027344 23.789062 40.453125 23.359375 40.597656 22.8125 C 40.738281 22.265625 40.574219 21.683594 40.167969 21.292969 L 25.582031 6.707031 C 25.285156 6.410156 24.878906 6.242188 24.457031 6.25 Z M 24.457031 6.25 \"\/>\n<\/g>\n<\/svg>\n            <\/button>\n        <\/div>\n\n\n\n\n        <div class=\"narrow-view\" :class=\"{active:narrow.open}\">\n            <div class=\"bkg\" @click=\"closeNarrowView()\"><\/div>\n            <div class=\"inner\" :class=\"{ready:appReady}\">\n                <div class=\"top\"><\/div>\n                <div class=\"chapters\" v-show=\"chapters.length\">\n                    <button @click=\"scrollToChapter(chapter)\" v-for=\"chapter in chapters\" :class=\"[{active:chapter.active}, 'level-' + chapter.level]\">{{chapter.title}}<\/button>\n                <\/div>\n                <div class=\"bottom\"><\/div>\n            <\/div>\n        <\/div>\n\n\n\n\n    <\/div>\n\n\n<\/div>\n\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-1dbb791{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-1dbb791 e-con-full e-flex e-con e-parent\" data-id=\"1dbb791\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-62849dd elementor-widget elementor-widget-spacer\" data-id=\"62849dd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Home \/ Oncopeptides riktar unik forskning mot obotlig cancer Oncopeptides riktar unik forskning mot obotlig cancer On this page {{chapter.title}} {{chapter.title}} {{chapter.title}} {{chapter.title}} Oncopeptides \u00e4r ett litet svenskt biotechbolag med en stor ambition: att rikta sin unika forskning mot cancerformer d\u00e4r behovet av nya behandlingar \u00e4r som st\u00f6rst. Med ett l\u00e4kemedel mot multipelt myelom &#8211; [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":7494,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"protected-content":[],"class_list":["post-8106","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/pages\/8106","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/comments?post=8106"}],"version-history":[{"count":34,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/pages\/8106\/revisions"}],"predecessor-version":[{"id":8176,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/pages\/8106\/revisions\/8176"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/media\/7494"}],"wp:attachment":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/media?parent=8106"}],"wp:term":[{"taxonomy":"protected-content","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/protected-content?post=8106"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}